Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) have multisystem complications that are serious, progressive, and often disabling. Recent advances in understanding the mechanisms of DM have guided the development of experimental therapies that have reversed manifestations in mouse models of DM type 1 (DM1). There is now renewed urgency to enhance the translational resources needed to bring treatments into clinical trials. To help achieve these goals, we propose to enhance the resources of our current National Registry of DM and FSHD Patients and Family Members and Repository within our Wellstone Scientific Core. The goals of our National Registry are to develop an extensive database of de-identified patient information;assist researchers in the recruitment of patients into clinical studies;and promote community outreach with care providers, researchers, patients,- and family members to discuss disease manifestations. Select strengths of the Registry include;stringent review of clinical and genetic medical records;ability to tailor recruitment based on common inclusion and exclusion criteria;and annually updated information. Our National Registry has currently enrolled over 1,900 patients. Within the past four years, we have facilitated 19 research studies, led by 15 different investigators at 11 sites, including key recruitment of patients into our Wellstone clinical studies. The Repository includes transgenic mouse models, cells derived from these models, and human tissue samples. We have existing methods to collect, store, and distribute these materials. Over 20 investigators, within and outside our Wellstone Center, have used Repository resources the past Our Scientific Core will be vital in the renewal plans of our Wellstone Center to facilitate recruitment of patients and collection of biomaterials within our newly established DM Clinical Research Network. By helping to remove barriers to research, our Scientific Core will improve the quality and quantity of research on DM and stimulate participation of new investigators, patients, family members, and care providers.

Public Health Relevance

Providing researchers with easy access to biological materials (e.g., mouse models and muscle tissues) and connecting patients with researcher are vitally important to move research forward. Our Scientific Core will provide safe, confidential, and open access to materials and interact with patients, with a common goal to guide research and to develop clinical guidelines and new therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS048843-12
Application #
8733764
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$261,884
Indirect Cost
$91,275
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Johnson, Nicholas E; Ekstrom, Anne-Berit; Campbell, Craig et al. (2016) Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol 58:698-705
Slean, Meghan M; Panigrahi, Gagan B; Castel, Arturo López et al. (2016) Absence of MutSβ leads to the formation of slipped-DNA for CTG/CAG contractions at primate replication forks. DNA Repair (Amst) 42:107-18
Fitzgerald, Bryan P; Conn, Kelly M; Smith, Joanne et al. (2016) Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy. J Neurol 263:2528-2537
Heatwole, Chad; Bode, Rita; Johnson, Nicholas E et al. (2016) Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve 53:183-90
Gloss, David; Moxley 3rd, Richard T; Ashwal, Stephen et al. (2016) Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:465-72
Heatwole, Chad; Johnson, Nicholas; Bode, Rita et al. (2015) Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). Neurology 85:2136-46
Yadava, Ramesh S; Foff, Erin P; Yu, Qing et al. (2015) TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet 24:2035-48
Pandey, Sanjay K; Wheeler, Thurman M; Justice, Samantha L et al. (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355:329-40
Wojtkowiak-Szlachcic, Agnieszka; Taylor, Katarzyna; Stepniak-Konieczna, Ewa et al. (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43:3318-31
Smith, Amanda E; McMullen, Kara; Jensen, Mark P et al. (2014) Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 93:387-95

Showing the most recent 10 out of 74 publications